Skip to content
value.today

Harvard Bioscience, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -8.6% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $38 M means free cash flow growing 0.7% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew -8.6% a year over the last three years.

Cash-flow value of the shares
$7 M
-82% against the market value
Value of the whole business
$34 M
before net debt
Value from after year 10
33%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-13.6%-11.1%-8.6%-6.1%-3.6%
8.15%-92%-77%-58%-35%-7%
9.15%-101%-88%-72%-52%-29%
10.15%-107%-96%-82%-65%-45%
11.15%-112%-102%-90%-76%-58%
12.15%-116%-107%-96%-84%-69%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

Price to salesPrice to sales of Medical Instruments: $170 M to $574 M, median $300 MPrice to bookPrice to book of Medical Instruments: $27 M to $91 M, median $61 MCash-flow value$0 M$155 M$310 M$465 M$620 MMarket value $38 M

Your own DCF model

A full discounted-cash-flow model of Harvard Bioscience, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Instruments

Multiples of its companies with a market value at most 60 days old, times Harvard Bioscience, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Harvard Bioscience, Inc.Applied toValue (25th to 75th)Companies
Price to sales2.0× / 3.5× / 6.6×0.4×revenue $87 M$170 M to $574 M23
Price to book2.0× / 4.4× / 6.6×2.7×book equity $14 M$27 M to $91 M23

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Harvard Bioscience, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

0.4×

Now above its median of 0.4×; range 0.2× to 3.5× over 27 months.

0×1×2×3×4×2020202120222023202420252026Price to sales 0×Median 0×

Price to book

2.7×

Now above its median of 1.2×, in the top quarter of its range; range 0.3× to 22.1× over 27 months.

0×6×11×17×22×2020202120222023202420252026Price to book 3×Median 1×

as of Oct 26, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 26, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$87 M$-57 M$7 M$1 M$5 M$27 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$94 M$-12 M$1 M$3 M$-1 M$33 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$112 M$-3 M$14 M$2 M$12 M$33 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$113 M$-10 M$1 M$2 M$-0 M$42 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$119 M$-0 M$1 M$1 M$0 M$41 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$102 M$-8 M$9 M$1 M$8 M$40 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $38 M on Oct 26, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.